I
InflaRx
Biotech & Life Sciences · Planegg, Germany · Founded 2007 · IPO 2018
Developing new therapeutics in the terminal complement space MoreLess
InflaRx N.V., headquartered in Jena, Germany, is a clinical-stage biopharmaceutical company specializing in the development of monoclonal antibodies that target activation products of the complement system. The company focuses on addressing acute and chronic inflammation through innovative therapeutic solutions. InflaRx's primary clients include healthcare providers and research institutions that require advanced treatments for life-threatening inflammatory diseases. Operating in the biopharmaceutical market, InflaRx employs a business model centered on research and development, clinical trials, and eventual commercialization of its drug candidates. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. InflaRx's lead drug candidate, IFX-1, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical phase II development. Another promising candidate, IFX-2, is in preclinical development and aims to offer highly potent anti-complement C5a antibody solutions.
Keywords: monoclonal antibodies, complement system, inflammatory diseases, biopharmaceutical, clinical trials, IFX-1, IFX-2, C5a, therapeutic solutions, healthcare providers.
Company overview
InflaRx company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2007
- Headquarters
- Planegg, Germany
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 31.8
Valuation & funding
InflaRx funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | May 2026 | $150M | — | ADAR1 Capital Management · Great Point Partners · Columbia Threadneedle Investments · Coastlands Capital | ↗ |
| POST IPO EQUITY✓Other financing | Feb 2025 | $30M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Apr 2023 | $40M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Feb 2021 | $75M | — | Undisclosed | — |
| IPO✓Exit | Apr 2018 | $104M | $351M | Undisclosed | — |
| SERIES D✓Equity / VC | Oct 2017 | Bain Capital · Cormorant Asset Management · RA Capital Management · Bain Capital Life Sciences | ↗ | ||
| SERIES C✓Equity / VC | Jul 2016 | Undisclosed | — | ||
| SERIES B✓Equity / VC | Jul 2014 | bm-t Beteiligungsmanagement Thüringen | — | ||
| SERIES A✓Equity / VC | Mar 2009 | Affentranger Associates | — | ||
| SEED✓Equity / VC | Mar 2008 | Affentranger Associates | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
InflaRx website traffic
Latest recorded traffic for InflaRx is 3.9K monthly website visits, up 129.4% over the last three months. InflaRx's team declined 24.6% over the past year.
Comparisons
InflaRx compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
InflaRx's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where InflaRx has talent and traffic
team presence
In the news
Latest news about InflaRx
Recent press, funding announcements, and product moves mentioning InflaRx — open to read from the original sources.
Market sentiment
What the market is saying about InflaRx
An AI-synthesized read of the highest-engagement posts about InflaRx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InflaRx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.